Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101

International Journal of Molecular Medicine

Volumn 28, Issue 5, 2011, Pages 727-731

  Bar Yehuda, Sara ^a   Luger, Dror ^b   Ochaion, Avivit ^a   Cohen, Shira ^a   Patokaa, Renana ^a   Zozulya, Galina ^a   Silver, Phylis B ^b   De Morales, Jose Maria Garcia Ruiz ^b   Caspi, Rachel R ^b   Fishman, Pnina ^a  

^a Can Fite BioPharma   (Israel)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

A3 adenosine receptor; CF101; Inflammation; Uveitis

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR; ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; PROTEIN P110; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; EX VIVO STUDY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; T LYMPHOCYTE; UVEA DISEASE;

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; INTERLEUKIN-10; INTERLEUKIN-2; LYMPH NODES; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ADENOSINE A3; SPLEEN; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 80053107312     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.753     Document Type: Article

References (27)

1. Jabs DA, Nussenblatt RB and Rosenbaum JT: Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 140: 509-516, 2005. (Pubitemid 41224845)
2. Nussenblatt RB and Whitcup SM (eds). Uveitis: Fundamentals and Clinical Practice. 3rd edition, Mosby/Elsevier, 2004.
3. Gery I, Nussenblatt RB, Chan CC and Caspi RR: Autoimmune diseases of the eye. In: The Molecular Pathology of Autoimmune Diseases. Theofilopoulos AN and Bona CA (eds). 2nd edition, Taylor and Francis, New York, pp1575-1609, 2002.
4. Taylor SR, Isa H, Joshi L and Lightman S: New developments in corticosteroid therapy for uveitis. Ophthalmologica 224: 46-53, 2010.
5. Larson T, Nussenblatt RB and Sen HN: Emerging drugs for uveitis. Expert Opin Emerg Drugs 16: 309-322, 2011.
6. Rosenbaum JT: Future for biological therapy for uveitis. Curr Opin Ophthalmol 21: 473-477, 2010.
7. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S and Baharav E: The PI3K-NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 8: 1-9, 2006.
8. Rath-Wolfson L, Bar Yehuda S, Madi L, Ochaion A, Cohen S, Zabutti A and Fishman P: IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin Exp Rheumatol 24: 400-406, 2006. (Pubitemid 44363541)
9. Bar-Yehuda S, Rath-Wolfson L, Del Valle L, et al: Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis Rheum 60: 3061-3071, 2009.
10. Mabley J, Soriano F, Pacher P, et al: The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 466: 323-329, 2003. (Pubitemid 36412095)
11. Schlötzer-Schrehardt U, Zenkel M, Decking U, et al: Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci 46: 2023-2034, 2005.
12. Zenkel M, Pöschl E, Von der Mark K, Hofmann-Rummelt C, Naumann GO, Kruse FE and Schlötzer-Schrehardt U: Differential gene expression in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci 46: 3742-3752, 2005. (Pubitemid 44264681)
13. Zhang X, Zhang M, Laties AM and Mitchell CH: Balance of purines may determine life or death of retinal ganglion cells as A3 adenosine receptors prevent loss following P2X7 receptor stimulation. J Neurochem 98: 566-575, 2006.
14. Zhang M, Budak MT, Lu W, Khurana TS, Zhang X, Laties AM and Mitchell CH: Identification of the A3 adenosine receptor in rat retinal ganglion cells. Mol Vis 12: 937-948, 2006.
15. Zhang M, Hu H, Zhang X, et al: The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. Neurochem Int 56: 35-41, 2010.
16. Hu H, Lu W, Zhang M, et al: Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res 91: 425-432, 2010.
17. Schmid SL, Fuchs R, Male P and Mellman I: Two distinct subpopulations of endosomes involved in membrane recycling and transport to lysosomes. Cell 52: 73-83, 1988. (Pubitemid 18054592)
18. Ward SG and Finan P: Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 3: 426-434, 2003. (Pubitemid 36908947)
19. Liu B, Faia L, Hu M and Nussenblatt RB: Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells. Mol Vis 16: 184-193, 2010.
20. Ke Y, Jiang G, Sun D, et al: Retinal Astrocytes respond to IL-17 differently than retinal pigment epithelial cells. J Leukoc Biol 86: 1377-1384, 2009.
21. Renga B, Migliorati M, Mencarelli A and Fiorucci S: Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages. Biochim Biophys Acta 1792: 564-573, 2009.
22. Willermain F, Dulku S, Gonzalez NS, et al: 15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanism. Prostaglandins Other Lipid Mediat 80: 136-143, 2006. (Pubitemid 44376432)
23. Caspi RR: Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21: 197-208, 2002.
24. Luger D, Silver PB, Tang J, et al: Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 205: 799-810, 2008. (Pubitemid 351549879)
25. Rizzo LV, Xu H, Chan CC, Wiggert B and Caspi RR: IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol 10: 807-814, 1998. (Pubitemid 28279484)
26. Sun B, Sun SH, Chan CC and Caspi RR: Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res 70: 493-502, 2000. (Pubitemid 30658891)
27. Avni I, Garzozi HJ, Barequet IS, et al: Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology 117: 1287-1293, 2010.